Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95


Relating prognosis in chromophobe renal cell carcinoma to the chromophobe tumor grading system.

Weinzierl EP, Thong AE, McKenney JK, Jeon SH, Chung BI.

Korean J Urol. 2014 Apr;55(4):239-44. doi: 10.4111/kju.2014.55.4.239. Epub 2014 Apr 10.


Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation.

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x. Epub 2011 Nov 1.


Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.

Jiang HM, Wei JH, Zhang ZL, Fang Y, Zhou BF, Chen ZH, Lu J, Liao B, Zhou FJ, Luo JH, Chen W.

Int Urol Nephrol. 2016 Feb;48(2):191-9. doi: 10.1007/s11255-015-1161-3. Epub 2015 Nov 20. Review.


A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.

Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, Lyles RH.

Am J Surg Pathol. 2010 Sep;34(9):1233-40. doi: 10.1097/PAS.0b013e3181e96f2a.


The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.

Steffens S, Janssen M, Roos FC, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff JW, Hofmann R, Stöckle M, Schrader M, Hartmann A, Hasenfus A, Kuczyk MA, Junker K, Schrader AJ; German Renal Cell Cancer Network.

Hum Pathol. 2014 Dec;45(12):2411-6. doi: 10.1016/j.humpath.2014.08.002. Epub 2014 Aug 23.


[Analysis of clinicopathological features and prognosis in 68 patients with chromophobe renal cell carcinoma].

Huang JW, Zhang J, Dong BJ, Kong W, Niu SX, Chen YH, Xue W, Liu DM, Huang YR.

Zhonghua Zhong Liu Za Zhi. 2012 Jul;34(7):510-3. doi: 10.3760/cma.j.issn.0253-3766.2012.07.008. Chinese.


The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma.

Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Dec;186(6):2168-74. doi: 10.1016/j.juro.2011.07.068. Epub 2011 Oct 19.


Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease.

Stec R, Grala B, Maczewski M, Bodnar L, Szczylik C.

J Exp Clin Cancer Res. 2009 Oct 7;28:134. doi: 10.1186/1756-9966-28-134. Review.


Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.

Cheville JC, Lohse CM, Sukov WR, Thompson RH, Leibovich BC.

Am J Surg Pathol. 2012 Jun;36(6):851-6. doi: 10.1097/PAS.0b013e3182496895.


Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma.

Jain S, Roy S, Amin M, Acquafondata M, Yin M, Laframboise W, Bastacky S, Pantanowitz L, Dhir R, Parwani A.

Am J Surg Pathol. 2013 Dec;37(12):1824-30. doi: 10.1097/PAS.0000000000000108.


[Clinical features on chromophobe renal cell carcinoma].

Wang ZH, DU LH, Hu ZQ, Chen XG, Zhao X, Wang SG, Zhuang QY, Ye ZQ.

Zhonghua Wai Ke Za Zhi. 2011 Apr 1;49(4):320-3. Chinese.


MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma.

Ge YZ, Xin H, Lu TZ, Xu Z, Yu P, Zhao YC, Li MH, Zhao Y, Zhong B, Xu X, Zhou LH, Wu R, Xu LW, Wu JP, Li WC, Zhu JG, Jia RP.

Sci Rep. 2015 May 18;5:10328. doi: 10.1038/srep10328.


Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution.

Przybycin CG, Cronin AM, Darvishian F, Gopalan A, Al-Ahmadie HA, Fine SW, Chen YB, Bernstein M, Russo P, Reuter VE, Tickoo SK.

Am J Surg Pathol. 2011 Jul;35(7):962-70. doi: 10.1097/PAS.0b013e31821a455d.


Cyst-associated renal cell carcinoma: clinicopathologic characteristics and evaluation of prognosis in 27 cases.

Onishi T, Oishi Y, Goto H, Tomita M, Abe K, Sugaya S.

Int J Urol. 2001 Jun;8(6):268-74.


Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.

Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P.

Ann Surg Oncol. 2004 Jan;11(1):71-7.


HNF1β and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe renal cell carcinoma in FNA and core needle biopsies.

Conner JR, Hirsch MS, Jo VY.

Cancer Cytopathol. 2015 May;123(5):298-305. doi: 10.1002/cncy.21530. Epub 2015 Mar 4.


Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients.

Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.

Mod Pathol. 2013 Aug;26(8):1144-9. doi: 10.1038/modpathol.2012.230. Epub 2013 Feb 1. Erratum in: Mod Pathol. 2013 Aug;26(8):1152.


Significance of nuclear grade and tumor size in Korean patients with chromophobe renal cell carcinoma: a comparison with conventional renal cell carcinoma.

Ku JH, Moon KC, Kwak C, Kim HH.

Urol Oncol. 2011 Sep-Oct;29(5):487-91. doi: 10.1016/j.urolonc.2009.05.011. Epub 2009 Sep 19.


Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases.

Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H.

Am J Surg Pathol. 2008 Dec;32(12):1822-34. doi: 10.1097/PAS.0b013e3181831e68.


Supplemental Content

Support Center